|Application ||WB, E|
|Calculated MW||35057 Da|
|Antigen Region||1-30 aa|
|Other Names||N-myc-interactor, Nmi, N-myc and STAT interactor, NMI|
|Target/Specificity||This NMI antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human NMI.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||NMI Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May be involved in augmenting coactivator protein recruitment to a group of sequence-specific transcription factors. Augments cytokine-mediated STAT transcription. Enhances CBP/p300 coactivator protein recruitment to STAT1 and STAT5.|
|Tissue Location||Expressed in all adult and fetal tissues except brain and skin. More abundant in fetal tissues especially liver|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NMYC interactor (NMI) encodes a protein that interacts with NMYC and CMYC (two members of the oncogene Myc family), and other transcription factors containing a Zip, HLH, or HLH-Zip motif. The NMI protein also interacts with all STATs except STAT2 and augments STAT-mediated transcription in response to cytokines IL2 and IFN-gamma. The NMI mRNA has low expression levels in all human fetal and adult tissues tested except brain and has high expression in cancer cell line-myeloid leukemias. [provided by RefSeq].
Davila, S., et al. Genes Immun. 11(3):232-238(2010)
Fillmore, R.A., et al. Int. J. Cancer 125(3):556-564(2009)
Quaye, L., et al. Br. J. Cancer 100(6):993-1001(2009)
Vega, A., et al. Gynecol. Oncol. 112(1):210-214(2009)
Quaye, L., et al. Clin. Cancer Res. 14(18):5833-5839(2008)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.